Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors versus single agent chemotherapy as second-line treatment for non–small-cell lung cancer wild-type or unknown status for EGFR

The aim of this systematic review is to evaluate the effectiveness and safety of EGFR-TKIs versus single-agent chemotherapy as second-line treatments in patients with advanced NSCLC and wild-type or unknown status for EGFR.

This is a protocol.